Patients: A total of 9650 adult patients with established CV disease without CKD (56.7%), CKD only (13%), or both CV disease and CKD (27%) were randomized 1:1 to receive semaglutide tablets 14 mg (n=4825) or placebo (n=4825) once daily, both in addition to standard-of-care treatments for glycemic control and CV risk factors including blood pressure medication, lipid-lowering agents, and antiplatelet/anticoagulant therapy
Weekly medications like semaglutide and dulaglutide have longer half-lives, taking longer to reach steady-state concentrations but offering more stable drug levels throughout the week
The best option for you depends on your medical profile, tolerability, and access
Whether you opt for a medical weight loss program or a more traditional approach, our solutions are rooted in science and tailored to meet your unique goals and body chemistry
With Klinic managing the insurance verification process beforehand, surprises are avoided for those using Medicare, Medicaid, or commercial insurance plans
Resistance mechanisms towards CD38-Directed antibody therapy in multiple myeloma